{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:03:05Z","timestamp":1790139785931,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81400408"],"award-info":[{"award-number":["81400408"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81570829"],"award-info":[{"award-number":["81570829"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["17411952900"],"award-info":[{"award-number":["17411952900"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To investigate aqueous humour (AH) cytokine profiles in eyes with Coats disease and analyze the association between cytokine concentrations and the severity of the disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study included 36 patients (36 eyes) with Coats disease and 15 control patients (15 eyes) with congenital cataract. AH samples were obtained preoperatively and the concentrations of 22 different cytokines were measured through Cytometric Bead Array technology. Clinical characteristics of Coats disease, including the extent of retinal exudation and exudative retinal detachment (ERD), were recorded for analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The concentrations of 8 cytokines (VEGF, IL-6, IL-8, MCP-1, MIP-1\u03b1, IP-10, VCAM-1 and ICAM-1) were significantly higher in the Coats disease group than in the control group (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.002). Except for VCAM-1 and ICAM-1, the concentration of the other cytokines listed above showed a significant increase from stage 2 to stage 3 (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). Meanwhile, the concentrations of VEGF, IL-8, MCP-1 and MIP-1\u03b1 showed a significant and positive association with the extent of retinal exudation and ERD (all\n                      <jats:italic>r<\/jats:italic>\n                      \u2009&gt;\u20090.4,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). Among these, IL-8 showed a strong association with the extent of retinal exudation and ERD (all\n                      <jats:italic>r<\/jats:italic>\n                      \u2009&gt;\u20090.7,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). The concentrations of IL-1\u03b1, IL-1\u03b2, IL-2, IL-4, IL-5, IL-10, IL-12, Fractalkine, RANTES, G-CSF and GM-CSF were very low in both groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Various cytokines in the AH, including elevated VEGF, IL-6, IL-8, MCP-1, MIP-1\u03b1, IP-10, VCAM-1 and ICAM-1, may be involved in the pathogenesis and progression of Coats disease. Increasing severity of Coats disease is significantly associated with the AH concentrations of VEGF, IL-8, MCP-1 and MIP-1\u03b1. Further clinical treatment aimed to reduce vascular leakage and antagonize neovascularization and inflammation may be useful in preventing the progression of Coats disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-020-01421-0","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T15:03:07Z","timestamp":1588690987000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Aqueous humour cytokines profiles in eyes with Coats disease and the association with the severity of the disease"],"prefix":"10.1186","volume":"20","author":[{"given":"Tingyi","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiquan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,5]]},"reference":[{"issue":"5","key":"1421_CR1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S0002-9394(00)00883-7","volume":"131","author":"JA Shields","year":"2001","unstructured":"Shields JA, Shields CL, Honavar SG, Demirci H. Clinical variations and complications of coats disease in 150 cases: the 2000 Sanford Gifford memorial lecture. Am J Ophthalmol. 2001;131(5):561\u201371.","journal-title":"Am J Ophthalmol"},{"key":"1421_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1746-1596-1-24","volume":"1","author":"BF Fernandes","year":"2006","unstructured":"Fernandes BF, Odashiro AN, Maloney S, Zajdenweber ME, Lopes AG, Burnier MN. Clinical-histopathological correlation in a case of coats\u2019 disease. Diagn Pathol. 2006;1:24.","journal-title":"Diagn Pathol"},{"issue":"4","key":"1421_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000336906","volume":"227","author":"S Ghorbanian","year":"2012","unstructured":"Ghorbanian S, Jaulim A, Chatziralli IP. Diagnosis and treatment of coats\u2019 disease: a review of the literature. Ophthalmologica. 2012;227(4):175\u201382.","journal-title":"Ophthalmologica"},{"issue":"1","key":"1421_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/1043-4666(92)90028-P","volume":"4","author":"D Wakefield","year":"1992","unstructured":"Wakefield D, Lloyd A. The role of cytokines in the pathogenesis of inflammatory eye disease. Cytokine. 1992;4(1):1\u20135.","journal-title":"Cytokine"},{"issue":"10","key":"1421_CR5","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s00417-010-1366-1","volume":"248","author":"YG He","year":"2010","unstructured":"He YG, Wang H, Zhao B, Lee J, Bahl D, McCluskey J. Elevated vascular endothelial growth factor level in coats\u2019 disease and possible therapeutic role of bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2010;248(10):1519\u201321.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"1421_CR6","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1111\/aos.12158","volume":"92","author":"Q Zhao","year":"2014","unstructured":"Zhao Q, Peng XY, Chen FH, Zhang YP, Wang L, You QS, Jonas JB. Vascular endothelial growth factor in coats\u2019 disease. Acta Ophthalmol. 2014;92(3):e225\u20138.","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"1421_CR7","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/aos.13151","volume":"95","author":"J Feng","year":"2017","unstructured":"Feng J, Zheng X, Li B, Jiang Y. Differences in aqueous concentrations of cytokines in paediatric and adult patients with coats\u2019 disease. Acta Ophthalmol. 2017;95(6):608\u201312.","journal-title":"Acta Ophthalmol"},{"key":"1421_CR8","doi-asserted-by":"crossref","unstructured":"Zhang J, Jiang C, Ruan L, Huang X. Associations of cytokine concentrations in aqueous humour with retinal vascular abnormalities and exudation in coats\u2019 disease. Acta Ophthalmol. 2019;97(3):319\u201324.","DOI":"10.1111\/aos.13971"},{"issue":"3","key":"1421_CR9","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1136\/bjophthalmol-2012-302250","volume":"97","author":"R Ray","year":"2013","unstructured":"Ray R, Baranano DE, Hubbard GB. Treatment of coats\u2019 disease with intravitreal bevacizumab. Br J Ophthalmol. 2013;97(3):272\u20137.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1421_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00417-013-2409-1","volume":"252","author":"XX Zheng","year":"2014","unstructured":"Zheng XX, Jiang YR. The effect of intravitreal bevacizumab injection as the initial treatment for coats\u2019 disease. Graefes Arch Clin Exp Ophthalmol. 2014;252(1):35\u201342.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"1421_CR11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/aos.13067","volume":"94","author":"Q Yang","year":"2016","unstructured":"Yang Q, Wei W, Shi X, Yang L. Successful use of intravitreal ranibizumab injection and combined treatment in the management of coats\u2019 disease. Acta Ophthalmol. 2016;94(4):401\u20136.","journal-title":"Acta Ophthalmol"},{"issue":"11","key":"1421_CR12","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1097\/IAE.0000000000000248","volume":"34","author":"MC Gaillard","year":"2014","unstructured":"Gaillard MC, Mataftsi A, Balmer A, Houghton S, Munier FL. ranibizumab in the management of advanced coats disease stages 3B and 4: long-term outcomes. Retina. 2014;34(11):2275\u201381.","journal-title":"Retina"},{"issue":"8","key":"1421_CR13","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s00417-015-3233-6","volume":"254","author":"S Park","year":"2016","unstructured":"Park S, Cho HJ, Lee DW, Kim CG, Kim JW. Intravitreal bevacizumab injections combined with laser photocoagulation for adult-onset coats\u2019 disease. Graefes Arch Clin Exp Ophthalmol. 2016;254(8):1511\u20137.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"1421_CR14","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0002-9394(01)00896-0","volume":"131","author":"JA Shields","year":"2001","unstructured":"Shields JA, Shields CL, Honavar SG, Demirci H, Cater J. Classification and management of coats disease: the 2000 proctor lecture. Am J Ophthalmol. 2001;131(5):572\u201383.","journal-title":"Am J Ophthalmol"},{"issue":"22","key":"1421_CR15","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480\u20137.","journal-title":"N Engl J Med"},{"issue":"1","key":"1421_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1167\/iovs.12-10613","volume":"54","author":"S Kase","year":"2013","unstructured":"Kase S, Rao NA, Yoshikawa H, Fukuhara J, Noda K, Kanda A, Ishida S. Expression of vascular endothelial growth factor in eyes with coats\u2019 disease. Invest Ophthalmol Vis Sci. 2013;54(1):57\u201362.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"1421_CR17","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.ophtha.2011.09.059","volume":"119","author":"NG Ghazi","year":"2012","unstructured":"Ghazi NG, Al Shamsi H, Larsson J, Abboud E. Intravitreal triamcinolone in coats\u2019 disease. Ophthalmology. 2012;119(3):648\u20139.","journal-title":"Ophthalmology"},{"issue":"7","key":"1421_CR18","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00417-011-1629-5","volume":"249","author":"MR Bohm","year":"2011","unstructured":"Bohm MR, Uhlig CE. Use of intravitreal triamcinolone and bevacizumab in coats\u2019 disease with central macular edema. Graefes Arch Clin Exp Ophthalmol. 2011;249(7):1099\u2013101.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"1421_CR19","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1136\/bjo.2009.168013","volume":"94","author":"IS Othman","year":"2010","unstructured":"Othman IS, Moussa M, Bouhaimed M. Management of lipid exudates in coats disease by adjuvant intravitreal triamcinolone: effects and complications. Br J Ophthalmol. 2010;94(5):606\u201310.","journal-title":"Br J Ophthalmol"},{"key":"1421_CR20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3389\/fimmu.2014.00491","volume":"5","author":"G Arango Duque","year":"2014","unstructured":"Arango Duque G, Descoteaux A. Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol. 2014;5:491.","journal-title":"Front Immunol"},{"issue":"3","key":"1421_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.coi.2010.02.013","volume":"22","author":"JM Curtsinger","year":"2010","unstructured":"Curtsinger JM, Mescher MF. Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol. 2010;22(3):333\u201340.","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"1421_CR22","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.cyto.2015.02.007","volume":"74","author":"MI Vazquez","year":"2015","unstructured":"Vazquez MI, Catalan-Dibene J, Zlotnik A. B cells responses and cytokine production are regulated by their immune microenvironment. Cytokine. 2015;74(2):318\u201326.","journal-title":"Cytokine"},{"issue":"4 Suppl 92","key":"1421_CR23","first-page":"S54","volume":"33","author":"O Boyman","year":"2015","unstructured":"Boyman O, Kolios AGA, Raeber ME. Modulation of T cell responses by IL-2 and IL-2 complexes. Clin Exp Rheumatol. 2015;33(4 Suppl 92):S54\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"1421_CR24","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1073\/pnas.89.5.1890","volume":"89","author":"F Rousset","year":"1992","unstructured":"Rousset F, Garcia E, Defrance T, P\u00e9ronne C, Vezzio N, Hsu DH, Kastelein R, Moore KW, Banchereau J. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A. 1992;89(5):1890\u20133.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1421_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/archopht.123.2.279","volume":"123","author":"WK Lim","year":"2005","unstructured":"Lim WK, Nussenblatt RB, Chan CC. Immunopathologic features of inflammatory coats disease. Arch Ophthalmol. 2005;123(2):279\u201381.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"1421_CR26","first-page":"710","volume":"131","author":"N Maruo","year":"1992","unstructured":"Maruo N, Morita I, Shirao M, Murota S. IL-6 increases endothelial permeability in vitro. Endocrinology. 1992;131(2):710\u20134.","journal-title":"Endocrinology"},{"issue":"12","key":"1421_CR27","doi-asserted-by":"publisher","first-page":"5014","DOI":"10.1091\/mbc.e07-01-0004","volume":"18","author":"ML Petreaca","year":"2007","unstructured":"Petreaca ML, Yao M, Liu Y, Defea K, Martins-Green M. Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8\/CXCL8) is required for IL-8\/CXCL8-induced endothelial permeability. Mol Biol Cell. 2007;18(12):5014\u201323.","journal-title":"Mol Biol Cell"},{"issue":"1","key":"1421_CR28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1189\/jlb.0302117","volume":"73","author":"S Yoshida","year":"2003","unstructured":"Yoshida S, Yoshida A, Ishibashi T, Elner SG, Elner VM. Role of MCP-1 and MIP-1alpha in retinal neovascularization during postischemic inflammation in a mouse model of retinal neovascularization. J Leukoc Biol. 2003;73(1):137\u201344.","journal-title":"J Leukoc Biol"},{"issue":"7","key":"1421_CR29","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1167\/iovs.04-1333","volume":"46","author":"H Xu","year":"2005","unstructured":"Xu H, Dawson R, Crane IJ, Liversidge J. Leukocyte diapedesis in vivo induces transient loss of tight junction protein at the blood-retina barrier. Invest Ophthalmol Vis Sci. 2005;46(7):2487\u201394.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"1421_CR30","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1136\/bjo.82.4.432","volume":"82","author":"E La Heij","year":"1998","unstructured":"La Heij E, Kuijpers RW, Baarsma SG, Kijlstra A, van der Weiden M, Mooy CM. Adhesion molecules in iris biopsy specimens from patients with uveitis. Br J Ophthalmol. 1998;82(4):432\u20137.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"1421_CR31","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.exer.2006.01.013","volume":"83","author":"SG Elner","year":"2006","unstructured":"Elner SG, Delmonte D, Bian ZM, Lukacs NW, Elner VM. Differential expression of retinal pigment epithelium (RPE) IP-10 and interleukin-8. Exp Eye Res. 2006;83(2):374\u20139.","journal-title":"Exp Eye Res"},{"issue":"10","key":"1421_CR32","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1097\/IAE.0000000000001013","volume":"36","author":"A Daruich","year":"2016","unstructured":"Daruich A, Matet A, Tran HV, Gaillard MC, Munier FL. Extramacular fibrosis in coats\u2019 disease. Retina. 2016;36(10):2022\u20138.","journal-title":"Retina"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01421-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-020-01421-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01421-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T19:09:40Z","timestamp":1620155380000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-020-01421-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,5]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1421"],"URL":"https:\/\/doi.org\/10.1186\/s12886-020-01421-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.24719\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.24719\/v2","asserted-by":"object"}]},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,5]]},"assertion":[{"value":"21 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study adhered to the tenets of the Declaration of Helsinki and was approved by the Ethics Committee of Xinhua Hospital. Written informed consent was obtained from each patient and their guardians.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"178"}}